乌司奴单抗剂量递增对标准剂量皮下维持治疗应答不足的克罗恩病患者的疗效
这项多中心回顾性队列研究纳入142例活动性克罗恩病患者,这些患者接受标准静脉诱导后至少一次皮下乌司奴单抗90mg,因应答不足而进行剂量递增(缩短间隔至每4或6周、静脉再诱导或联合策略)。剂量递增后第16周,51.4%(73/142)患者临床应答,38.7%(55/142)达临床缓解;末次随访时52%(51/98)有数据者应答,42%(41/98)缓解。结论认为剂量递增对超过50%患者有效。
要点
- 剂量递增后第16周51.4%患者临床应答,38.7%达临床缓解。
- 末次随访时52%有数据者应答,42%达临床缓解。
- 对每8周标准维持剂量无应答者应考虑剂量递增策略。
核心结论
- 乌司奴单抗维持剂量递增对超过50%的标准剂量应答不足的克罗恩病患者有效。
- 对每8周乌司奴单抗维持剂量无应答的患者应考虑剂量递增策略。
研究设计与样本
- 多中心回顾性队列研究,纳入142例活动性克罗恩病患者(来自22个中心/14个国家)。
- 患者接受标准静脉诱导后至少一次皮下乌司奴单抗90mg,中位治疗30周后因应答不足进行剂量递增。
- 剂量递增方式包括缩短给药间隔至每4或6周、静脉再诱导或联合策略。
主要发现
- 剂量递增后第16周,73/142(51.4%)患者临床应答,其中55/142(38.7%)达临床缓解。
- 剂量递增时使用皮质类固醇的34例患者中,6/34(17.6%)达无皮质类固醇缓解。
- 142例中118例(83%)在16周后继续治疗;118例中74例(62.7%)有16周后随访数据。
- 末次随访时,有数据的98例中51例(52%)应答,其中41例(42%)达临床缓解。
临床怎么用
- 对每8周乌司奴单抗90mg维持治疗应答不足的活动性克罗恩病患者,可考虑缩短间隔至每4或6周、静脉再诱导或联合策略。
局限性
- 回顾性研究设计。
- 16周后随访数据仅覆盖部分患者(74/118,62.7%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ustekinumab is effective in Crohn's disease. However, a substantial proportion of patients will not respond or lose response to ustekinumab. The current evidence to support the effectiveness of dose-optimisation for ustekinumab nonresponse is limited. AIM: To assess the effectiveness of dose escalation of ustekinumab. METHODS: This was a multicentre retrospective cohort study. We included active Crohn's disease patients who received a standard-dose intravenous induction and at least one subcutaneous ustekinumab 90 mg dose. All enrolled patients received dose escalation by either shortening the interval between the doses to every 4 or 6 weeks, intravenous reinduction or a combination of strategies. The primary outcome of the study was clinical response at week 16 after dose escalation. RESULTS: A total of 142 patients (22 centres/14 countries) were included. The patients were dose-escalated after a median treatment duration of 30 weeks. At week 16 from escalation, 73/142 (51.4%) responded to treatment, including 55/142 (38.7%) in clinical remission. Corticosteroid-free remission was achieved in 6/34 (17.6%) patients on corticosteroids at the time of escalation; 118/142 (83%) continued treatment beyond week 16. Follow-up data beyond week 16 were available for 74/118 (62.7%) patients. On the last follow-up, 51/98 (52%) patients with available data responded to treatment, including 41/98 (42%) in clinical remission. CONCLUSIONS: Intensification of ustekinumab maintenance dosage was effective in over 50% of the patients. This strategy should be considered in patients who are nonresponsive to every 8 weeks ustekinumab maintenance dosing.
引用
- Kopylov U, Hanzel J, Liefferinckx C, et al. Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy. Aliment Pharmacol Ther. 2020. PMID: 32412134. doi:10.1111/apt.15784
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。